Free shipping on all orders over $ 500

Crovalimab

Cat. No. M24849

All AbMole products are for research use only, cannot be used for human consumption.

Crovalimab Structure
Synonym:

SKY59; RO7112689

Size Price Availability Quantity
100ug USD 170 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.

Chemical Information
CAS Number 1917321-26-6
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Masanobu Nishidate, et al. Bioanalysis. Validation of a method to analyze size distribution of crovalimab-complement C5-eculizumab complexes in human serum

[2] Gianluigi Ardissino, et al. Pharmaceuticals (Basel). Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy

[3] Urszula Szlendak, et al. Pol Arch Intern Med. Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment

[4] Alexander Röth, et al. Blood. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Related Complement System Products
Eculizumab

Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species.

SB290157 trifluoroacetate salt

SB290157 is a selective antagonist of complement anaphylatoxin C3a receptor, a 74 amino acid proinflammatory peptide that is a potent chemotaxin for eosinophils, macrophages and mast cells.

JPE-1375

JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice.

Compstatin

Compstatinis is a 13-residue cyclic peptide, binds to complement component C3 and inhibits complement activation with IC50 of 12 μM. Compstatin exhibits exclusive specificity for primate C3s and does not bind either to C3s from lower mammalian species or to two structural homologs of C3, human C4 and C5.

Avacopan

Avacopan (CCX168) is a first-in-class, potent, selective and orally available complement 5a receptor (C5aR1 or CD88) antagonist with an IC50 of 0.1 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Crovalimab, SKY59; RO7112689 supplier, Complement System, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.